Polyurethane-Coated Implants Reduce Complications in Mastectomy Reconstruction After Radiotherapy

New research indicates that women undergoing reconstructive surgery after a mastectomy for breast cancer are significantly less likely to experience complications if they receive a polyurethane-coated implant. This finding is particularly relevant for the approximately 55,000 women diagnosed with breast cancer annually in the UK, about 30% of whom undergo a mastectomy. Many of these patients subsequently receive radiotherapy, a treatment often associated with a higher risk of complications and additional surgery after breast reconstruction.

Women with polyurethane-coated implants were significantly less likely to develop hardened scar tissue, known as capsular contracture, and required less secondary surgery.

European Study Details

A comprehensive study conducted by European scientists involved approximately 1,500 women across 15 countries. Participants were treated for breast cancer between 2016 and 2024. All women in the study had a mastectomy, followed by breast implant reconstruction, and subsequently received radiotherapy.

One-third of these women received a polyurethane-coated implant, while just under 1,000 received standard implants. The health of these women was meticulously tracked for a period of two-and-a-half to three years.

Key Outcomes

Preliminary findings, which were presented at the European Breast Cancer Conference in Barcelona, highlight substantial benefits of the specialized implants:

• Women with polyurethane-coated implants were significantly less likely to develop hardened scar tissue, known as capsular contracture.
• Specifically, 32.8% of women with polyurethane-coated implants developed capsular contracture, a marked improvement compared to 47.5% of patients with standard implants.
• Patients with polyurethane-coated implants were also less likely to require secondary surgery for scar tissue removal or to experience a major breast infection.

Expert Statements

Dr. Kerstin Wimmer, a surgeon at the Medical University of Vienna, stated that the study suggests women with polyurethane-coated implants experienced fewer post-radiotherapy problems compared to those with standard implants. She emphasized that "the type of implant used may significantly influence the risk of complications after radiotherapy," providing crucial evidence to guide reconstructive planning for patients likely to need radiotherapy.

Professor Isabel Rubio, Head of Breast Surgical Oncology at Clínica Universidad de Navarra in Madrid, noted the broader impact of these findings. She highlighted that they "could help improve patient comfort, aesthetic results, and overall quality of life." Professor Rubio stressed the value of such evidence in guiding implant selection and treatment planning for personalized breast cancer care, aiming to minimize long-term side effects and enhance patient recovery.

Catherine Priestley, a senior clinical nurse specialist at Breast Cancer Now, underscored the importance of comparing implant compatibility with radiotherapy regarding complication risks. She stated that this information can empower women to make more informed and personalized choices, ultimately improving their quality of life after breast cancer treatment. Sarah Downey, president of the Association of Breast Surgery, acknowledged breast implants as "an important reconstruction option that can restore confidence and potentially improve quality of life," and expressed anticipation for further research in this area.